Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate

The American Journal of Medicine

Volumn 87, Issue 3 SUPPL. 2, 1989, Pages

  Buller, Harry R ^a   Cate, Jan W Ten ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; HEPARIN;

ANTITHROMBIN III DEFICIENCY; HUMAN; IMMUNOASSAY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM;

ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; DISSEMINATED INTRAVASCULAR COAGULATION; HUMAN; IMMUNOASSAY; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0024457904     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(89)80531-5     Document Type: Article

References (54)

1. Heparin, antithrombin and abnormal clotting
2. An international collaborative study establishing a reference preparation for antithrombin III
3. The determination of antithrombin III by radioimmunoassay and its clinical application
4. Determination of antithrombin III by sandwich enzyme immunoassay technique
5. Antithrombin III determination by rate (kinetic) nephelmetry
6. Abnormal antithrombin III (antithrombin III “Budapest”) as a cause of familial thrombophilia
7. Neonatal antithrombin III
8. Studies of the heterogeneity of antithrombin III concentrates
9. Treatment of congenital antithrombin III deficiency with concentrates
10. Antithrombin III:its metabolism and its function in blood coagulation
11. Assay of progressive antithrombin in plasma
12. A method of antithrombin estimation using plasma defibrinated with ancrod
13. Plasma antithrombin III:a quantitative assay of biological activity
14. Thrombin-induced proteolysis of human antithrombin III:an outstanding contribution of heparin
15. Antithrombin III. Evaluation of an automated antithrombin III method
16. Antithrombin assay—the use of human or bovine antithrombin and the observation of a second heparin co-factor
17. Rapid microanalysis of coagulation parameters by automated chromogenic substrate methods—application in neonatal patients
18. Antithrombin III in a clinical material
19. Antithrombin III in fresh and cultured human endothelial cells a natural anticoagulant from the vascular endothelium
20. Human hepatoma cells secrete single chain factor X prothrombin and antithrombin III
21. Antithrombin III metabolism in patients with liver cirrhosis
22. Metabolism of fibrinogen in cirrhosis of the liver
23. Turnover of radiolabelled plasminogen and prothrombin in cirrhosis of the liver
24. Antithrombin III transfusion in patients with hepatic cirrhosis
25. Antithrombin III infusion in patients undergoing peritoneovenous shunt operation:failure in the prevention of disseminated intravascular coagulation
26. Reduced antithrombin III levels during L-asparaginase therapy
27. Oral contraceptives and low antithrombin III activity (letter)
28. Antithrombin III in oral contraceptive users and during normotensive pregnancy
29. “Morning after” pill and antithrombin III (letter)
30. Antithrombin III levels in pre-eclampsia correlate with maternal and fetal morbidity
31. Oestrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer
32. Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma
33. Metabolism of antithrombin III in man:effects of venous thrombosis and of heparin administration
34. Heparin induced clearance in circulating antithrombin III
35. Hereditary ATIII deficiency and heparin
36. Acquired antithrombin III deficiency and thrombosis in nephrotic syndrome
37. Thrombophilie bei erworbener Antithrombin III Mangel von patienten mit nephrotischem syndrom
38. Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome
39. Antithrombin III (ATIII) as a diagnostic aid in disseminated intravascular coagulation
40. Low antithrombin III levels in neonates with idiopathic respiratory distress syndrome:poor prognosis
41. Intensive monitoring of coagulation and fibrinolysis in the first week of life
42. Studies on antithrombin III and human antithrombin III concentrate transfusion
43. Antithrombin III deficiency:clinical relevance and replacement therapy
44. The effects of antithrombin III, heparin and a novel heparinoid infusion on the bleeding tendency using an experimental model in the rat
45. Infusion of purified antithrombin III to patients with fracture of the neck of the femur
46. Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement
47. Antithrombin III transfusion in disseminated intravascular coagulation
48. Antithrombin III concentrate as adjuvant in DIC patients
49. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation
50. Antithrombin III infusion in patients undergoing peritoneovenous shunt operationfailure in the prevention of DIC
51. Substitution of antithrombin III in shock and DIC:a randomized study
52. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics